Results 161 to 170 of about 2,458 (200)

Advancements in B-Cell Non-Hodgkin's Lymphoma: From Signaling Pathways to Targeted Therapies. [PDF]

Adv Hematol
Alfaifi A, Bahashwan S, Alsaadi M, Ageel AH, Ahmed HH, Fatima K, Malhan H, Qadri I, Almehdar H.   +8 more
europepmc   +1 more source

Janus kinase inhibitors - a role for the treatment of cutaneous T-cell lymphomas? [PDF]

Oncol Rev
Packer SE, Brunner PM.
europepmc   +1 more source

Nodal Peripheral T-Cell Lymphoma: Therapeutic Challenges and Future Perspectives. [PDF]

Cancers (Basel)
Lam HPJ, Amin F, Arulogun SO, Gleeson M.
europepmc   +1 more source

KLRG1 Cell Depletion as a Novel Therapeutic Strategy in Patients with Mature T-Cell Lymphoma Subtypes. [PDF]

Clin Cancer Res
Assatova B, Willim R, Trevisani C, Haskett G, Kariya KM, Chopra K, Park SR, Tolstorukov MY, McCabe SM, Duffy J, Louissaint A, Huuhtanen J, Bhattacharya D, Mustjoki S, Koh MJ, Powers F, Morgan EA, Yang L, Pinckney B, Cotton MJ, Crabbe A, Ziemba JB, Brain I, Heavican-Foral TB, Iqbal J, Nemec R, Rider AB, Ford JG, Koh MJ, Scanlan N, Feith DJ, Loughran TP, Kim WS, Choi J, Roels J, Boehme L, Putteman T, Taghon T, Barnes JA, Johnson PC, Jacobsen ED, Greenberg SA, Weinstock DM, Jain S.   +43 more
europepmc   +1 more source

SGLT2 inhibitors and mortality in diabetic cancer patients: cardioprotective and anticancer effects. [PDF]

Eur Heart J Cardiovasc Pharmacother
Keramida K, Ahmed A, Filippatos G.
europepmc   +1 more source

HDAC inhibitors as anticancer drugs: chemical diversity, clinical trials, challenges and perspectives. [PDF]

RSC Adv
Abdallah AE.
europepmc   +1 more source

Beyond base camp: PI3K/mTOR inhibition for the treatment of pediatric high-grade gliomas. [PDF]

Neuro Oncol
Duchatel RJ, Savary C, Germon ZP, Riley M, Ziegler DS, Mueller S, Jackson ER, Dun MD.   +7 more
europepmc   +1 more source

Current and upcoming treatment approaches to common subtypes of PTCL (PTCL, NOS; ALCL; and TFHs).

Blood
Moskowitz AJ, Stuver RN, Horwitz SM.
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Duvelisib for the treatment of chronic lymphocytic leukemia

Expert Opinion on Pharmacotherapy, 2020
Duvelisib, a first in class, oral, dual PI3 k-delta/gamma inhibitor recently received FDA approval for previously treated CLL (chronic lymphocytic leukemia)/SLL (small lymphocytic lymphoma) and follicular lymphoma. Data coming from the phase III 'DUO' trial, in fact, showed a superior progression-free survival (PFS) in CLL patients treated with ...
Anna Maria Frustaci, Alessandra Tedeschi, Marina Deodato, Giulia Zamprogna, Cairoli R, Marco Montillo   +5 more
openaire   +3 more sources